Third Quarter 2026
Filed Oct 29, 2026Third Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million
Revenue increased 39% year-over-year to $139 million, Testing Services revenue increased 65%, GAAP net income was $19 million versus $2 million, adjusted EBITDA was $30 million versus $15 million, and the company raised both full-year revenue and Adjusted EBITDA guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $139.4M | – | 39% |
| Testing services revenueGAAP | $119.2M | – | 65% |
| Product revenueGAAP | $ — | – | – |
| Patient and digital solutions revenueGAAP | $20.17M | – | 31% |
| Testing Services volumeother | approximately 75,900 | – | 51% |
| Testing Services revenue excluding revenue recognized for tests performed in prior periodsGAAP | :null | – | approximately 58% |
| Testing Services revenue from tests performed in prior periodsGAAP | $15M | – | – |
| Specialty Oncology revenueGAAP | $12M | – | – |
| Cost of testing servicesGAAP | $24.68M | – | – |
| Cost of productGAAP | $ — | – | – |
| Cost of patient and digital solutionsGAAP | $15.60M | – | – |
| GAAP cost of salesGAAP | 40,287 | – | – |
| GAAP gross profitGAAP | $99.08M | – | – |
| GAAP gross marginGAAP | 71 % | – | – |
| Non-GAAP gross profitnon-GAAP | $102.5M | – | – |
| Non-GAAP gross marginnon-GAAP | 74 % | – | – |
| Research and developmentGAAP | $21.32M | – | – |
| Sales and marketingGAAP | $31.65M | – | – |
| General and administrativeGAAP | $37.99M | – | – |
| Total GAAP operating expensesGAAP | $90.96M | – | – |
| Total operating expensesGAAP | 131,250 | – | – |
| Non-GAAP research and development expensesnon-GAAP | $20.13M | – | – |
| Non-GAAP sales and marketing expensesnon-GAAP | $30.00M | – | – |
| Non-GAAP general and administrative expensesnon-GAAP | $25.14M | – | – |
| Total Non-GAAP operating expensesnon-GAAP | $75.27M | – | – |
| Income (loss) from operationsGAAP | 8,112 | – | – |
| Interest income, netGAAP | 2,208 | – | – |
| Other income (expense), netGAAP | 372 | – | – |
| Total other incomeGAAP | 2,580 | – | – |
| Income before income taxesGAAP | 10,692 | – | – |
| Income tax benefitGAAP | 8,600 | – | – |
| GAAP net incomeGAAP | $19.29M | – | – |
| GAAP net income marginGAAP | 14 % | – | – |
| GAAP basic net income per shareGAAP | $ 0.37 | – | – |
| GAAP diluted net income per shareGAAP | $ 0.35 | – | – |
| Non-GAAP net incomenon-GAAP | $38.37M | – | – |
| Non-GAAP basic net income per sharenon-GAAP | $ 0.74 | – | – |
| Non-GAAP diluted net income per sharenon-GAAP | $ 0.70 | – | – |
| Adjusted EBITDAnon-GAAP | $30.50M | – | – |
| Adjusted EBITDA marginnon-GAAP | 22 % | – | – |
| Net cash provided by operating activitiesGAAP | $12.72M | – | – |
| Capital expendituresGAAP | −$1.61M | – | – |
| Free cash flownon-GAAP | $11.10M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Testing ServicesGrowth included $12 million in Specialty Oncology revenue and contributions following the acquisition of NavDx; Testing Services revenue also included $15 million in prior period revenue. | $119M | – | 65% |
| Patient and Digital SolutionsDriven primarily by continued growth in CareDx Pharmacy services. | $20M | – | 31% |
| Lab ProductsThe Company completed the divestiture of its Lab Products business on June 30, 2026, and third quarter 2026 results do not include Lab Products revenue. | $ — | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Revenue$520 million to $530 million
- NoteAdjusted EBITDA of $90 million to $100 million
- NotePreviously disclosed revenue range of $490 million to $500 million
- NotePreviously disclosed Adjusted EBITDA range of $66 million to $78 million
What drove it
- Testing Services revenue increased 65% year-over-year, including $12 million in Specialty Oncology revenue.
- Testing Services volume increased 51% year-over-year, including contributions from Specialty Oncology.
- Patient and Digital Solutions revenue growth was driven primarily by continued growth in CareDx Pharmacy services.
- Adjusted EBITDA was driven by revenue growth, higher gross profit and disciplined operating expense management.
- The Company closed the acquisition of Naveris, Inc. on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration.
- The Company advanced AlloHeme toward a planned first-quarter 2027 commercial launch and HistoMap Kidney toward broader commercial availability in 2027.
Concerns
- Testing Services revenue included $15 million in prior period revenue, compared with $6 million in the third quarter of 2025.
- GAAP gross margin was 71 %, compared with 74 % in the three months ended June 30, 2026.
- Net cash provided by operating activities was $ 12,718, compared with $ 37,358 in the third quarter of 2025.
- The Company recorded $ 5,527 of business development and portfolio optimization expense, primarily related to the sale of its Lab Products business and acquisition of Naveris, Inc.
- The Company completed the divestiture of its Lab Products business on June 30, 2026; third quarter 2026 results do not include Lab Products revenue.
What to watch
- Execution toward the planned first-quarter 2027 commercial launch of AlloHeme and broader commercial availability of HistoMap Kidney in 2027.
- Testing Services volume and the contribution from Specialty Oncology following the acquisition of NavDx.
- The magnitude of revenue recognized for tests performed in prior periods.
- CareDx Pharmacy services growth within Patient and Digital Solutions.
- Migration of NavDx to the CareDx billing platform and continued Epic Aura adoption.
- Delivery against full-year 2026 revenue guidance of $520 million to $530 million and Adjusted EBITDA guidance of $90 million to $100 million.
Balance sheet and cash flow
- Cash and cash equivalents were $ 250,480 as of September 30, 2026, compared with $ 65,429 as of December 31, 2025.
- Marketable securities were $ — current and $ — non-current as of September 30, 2026, compared with $ 111,779 current and $ 24,165 non-current as of December 31, 2025.
- Total assets were $ 641,457 as of September 30, 2026, compared with $ 413,228 as of December 31, 2025.
- Total liabilities were 174,001 as of September 30, 2026, compared with 110,127 as of December 31, 2025.
- Contingent consideration, non-current was 14,035 as of September 30, 2026, compared with 161 as of December 31, 2025.
- Total stockholders’ equity was 467,456 as of September 30, 2026, compared with 303,101 as of December 31, 2025.
- Net cash provided by operating activities was $ 12,718, capital expenditures were $ (1,615), and free cash flow was $ 11,103 for the three months ended September 30, 2026.
Analysis
CareDx reported third-quarter total revenue of $139 million, up 39% year-over-year from $100 million. Testing Services revenue was $119 million, up 65% year-over-year, while Patient and Digital Solutions revenue was $20 million, up 31%. Testing Services volume increased 51% year-over-year to approximately 75,900. The revenue mix included $12 million in Specialty Oncology revenue and $15 million in Testing Services revenue recognized for tests performed in prior periods.
Profitability improved substantially year-over-year. GAAP net income was $19 million, compared with $2 million, and GAAP diluted net income per share was $0.35, compared with $0.03. Adjusted EBITDA was $30 million, compared with $15 million, with adjusted EBITDA margin of approximately 22%, compared with approximately 15%. GAAP gross margin was 71%, compared with 69% in the third quarter of 2025, while non-GAAP gross margin was 74%, compared with 71%.
Sequentially, GAAP total revenue was $139,362, compared with $131,948 in the three months ended June 30, 2026. GAAP gross margin was 71%, compared with 74%, while adjusted EBITDA increased to $30,496 from $24,804 and adjusted EBITDA margin increased to 22% from 19%. GAAP net income for the June quarter was $110,636 and included a $112,966 gain on sale of the Lab Products business in the adjusted EBITDA reconciliation.
The balance sheet reflected $250,480 of cash and cash equivalents at September 30, 2026, versus $65,429 at December 31, 2025. The company closed the Naveris acquisition on July 1, 2026 for $160 million in cash consideration and up to $100 million in contingent consideration. Third-quarter net cash provided by operating activities was $12,718 and free cash flow was $11,103.
Management raised full-year 2026 revenue guidance to $520 million to $530 million from $490 million to $500 million and raised Adjusted EBITDA guidance to $90 million to $100 million from $66 million to $78 million. The operational focus includes the planned first-quarter 2027 commercial launch of AlloHeme, broader HistoMap Kidney commercial availability in 2027, scaling Specialty Oncology, and the migration of NavDx to the CareDx billing platform.
Management, verbatim
We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.
John Hanna, President and Chief Executive Officer of CareDx
We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.
John Hanna, President and Chief Executive Officer of CareDx
Not in the filing
stated, not guessed- A separate previous-release outlook section was not provided; therefore, no actual-versus-prior-guidance comparison is presented.
- Debt balances were not reported in the provided balance sheet.
- Share repurchases and dividends were not reported.
- Full-year 2026 guidance for gross margin, operating expenses, tax rate, GAAP net income, GAAP EPS, operating cash flow and free cash flow was not reported.
- Prior-year and prior-quarter Testing Services volume figures were not reported.
- Year-over-year and sequential percentage changes for most statement-of-operations line items were not reported.
- A numeric value for Testing Services revenue excluding revenue recognized for tests performed in prior periods was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.